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before EGFR-TKI in patients with 
minor mutations. It is more diffi-
cult to administer platinum doublets 
as second-line treatment, compared 
with EGFR-TKI. In patients with 
SQC harboring minor mutations, pri-
ority of EGFR-TKI becomes much 
lower.
The diagnostic limitations of 
small biopsies and intratumoral het-
erogeneity make definitive diagnoses 
difficult.5 Clinicians should understand 
the limitations of pathologic diagno-
sis based on small biopsies, and need 
to cooperate with pathologists to bet-
ter reach a diagnosis for individual 
patients. EGFR-TKI sensitivity in 
EGFR-mutated SQC should be judged 
by the general factors of the patient.
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Several studies in patients with 
EGFR mutations demonstrated the 
efficacy of platinum doublets; and 
the response rate (RR) and median 
 progression-free survival (PFS) were 
approximately 30% and 6 months,2 
similar to our 14 EGFR-mutated SQC 
patients receiving platinum doublets 
as first-line treatment. Compared with 
our EGFR-TKI results (RR, 25% and 
median PFS, 1.4 months),3 we would 
generally choose platinum doublets 
as first-line treatment before EGFR-
TKIs in such patients. However, we 
should ponder how many EGFR-
mutated adenocarcinoma cells are 
included in an SQC case. If the 
EGFR-mutated SQC patient is sus-
pected as harboring EGFR-mutated 
adenocarcinoma propensity per the 
following factors: female, never 
smoker, high carcinoembryonic anti-
gen, and thyroid transcription factor-1 
positive, we could try EGFR-TKI as a 
first-line treatment. Conversely, male, 
current smoker, high cytokeratin 19 
fragment, and p63 positive patients 
would be better served by platinum 
doublets. We should recognize some 
EGFR-mutated SQC include an 
incomplete sampling of adeno-SQC 
and/or poorly differentiated adeno-
carcinoma morphologically mimick-
ing SQC. Approximately one third 
of the EGFR-mutated SQC patients 
in our study obtained a PFSof lon-
ger than 6 months, and most of them 
had adenocarcinoma propensities. To 
better identify EGFR-TKI–sensitive 
SQC patients, not only EGFR muta-
tion status, but also clinical factors 
and pathologic findings should be 
taken into consideration.
Unfortunately, both of our two 
patients with a G719X point mutation 
in exon 18 did not undergo EGFR-
TKIs in our study. Sensitivities of 
 EGFR-TKIs in minor EGFR muta-
tions such as G719X seem to be less 
effective than major mutations such 
as deletional mutations in exon 19 
and a L858R point mutation in exon 
21. In patients with minor muta-
tions, the RR and PFS were shown to 
be 30% to 50% and 3 to 5 months, 
comparable to platinum doublets.4 In 
our opinion, we would choose plati-
num doublets as first-line treatment, 
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In Response:
We are thankful for the thought-
ful suggestions by Zhou et al.1 They 
raised two intriguing questions: first, 
which is better, platinum doublets 
or epidermal growth factor recep-
tor (EGFR)–tyrosine kinase inhibitor 
(TKI) as first-line treatment in squa-
mous cell carcinoma (SQC) patients 
with EGFR-sensitive mutations; and 
second, how do we treat patients with 
minor EGFR mutations?
